Search jobs 15-Apr-2021 HUMMINGBIRD BIOSCIENCE PRESENTS PRE-CLINICAL DATA ON ITS NEXT-GENERATION BCMA-TACI DUAL-SPECIFIC T CELL ENGAGER AT 2021 AACR ANNUAL MEETING
HUMMINGBIRD BIOSCIENCE
2021 AACR ANNUAL MEETING
Singapore, April 10, 2021 – Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to improve treatment outcomes, today announced that the company will be presenting pre-clinical data on its BCMA-TACI dual-specific T cell engager, HMBD-009, at the 2021 American Association for Cancer Research (AACR) Annual Meeting taking place 9-14 April.
HMBD-009 is Hummingbird’s next-generation T cell program that uniquely targets both B cell maturation antigen (BCMA) and Transmembrane activator and CAML Interactor (TACI), proteins commonly overexpressed in multiple myeloma, the second most common hematologic malignancy and a leading cause
Posted on 244
Incyte (Nasdaq:INCY) today announced that multiple abstracts from across its oncology portfolio will be presented during Week 1 of the upcoming American Association for Cancer Research (AACR) Annual Meeting 2021, held virtually from April 10-15, 2021.
“At AACR 2021, we look forward to sharing clinical and pre-clinical data from INCB106385, our novel A2A/A2B adenosine receptor antagonist, and INCA00186, our novel CD73 monoclonal antibody both of which highlight our ongoing efforts targeting the adenosine pathway. Presentations at the congress will also feature updated data from our LIMBER development program, including results from our Phase 2 combination study of ruxolitinib, a janus kinase (JAK1/JAK2) inhibitor, and parsaclisib, a potent, highly selective oral inhibitor of phosphatidylinositol 3-kinase delta (PI3Kδ),” said Steven Stein, M.D., Chief Medical Officer, Incyte, adding, “We further look
Search jobs 10-Mar-2021 LAVA Therapeutics B.V. to Present Preclinical Findings Supporting Anti-Tumor Activity of Lead Clinical Candidate LAVA-051 at the American Association for Cancer Research (AACR) Virtual 2021 Annual Meeting
UTRECHT, The Netherlands & PHILADELPHIA (BUSINESS WIRE) LAVA Therapeutics B.V., a biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers (bsTCE) to transform cancer therapy, today announced that a poster featuring lead clinical candidate LAVA-051 will be presented at week 1 of the virtual American Association for Cancer Research (AACR) Annual Meeting, which will be held April 10-15, 2021.
The following abstract is now available on the AACR website at www.aacr.org.
LAVA Therapeutics B.V., a biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers (bsTCE) to transform cancer therapy, today announced that a poster featuring